Overcoming cancer drug resistance


Q4 & year-end report 2022

Learn more about our unique first-in-class lead compound SCO-101

Presenting CEO Francois Martelet


Scandion Oncology Capital Markets Day

September 8, 2021

Watch the presentations from Scandion Oncology’s Capital Markets Day


A great place to work

For talented, ambitious individuals who share our passion for science and drug development, we offer an exciting work environment, along with the opportunity to make a difference for the many cancer patients in need for novel treatments